The efficacy of abatacept in Japanese patients with rheumatoid arthritis: 104 weeks radiographic and clinical results in clinical practice

Mochizuki, Takeshi; Yano, Koichiro; Ikari, Katsunori; Hiroshima, Ryo; Takaoka, Hiromitsu; Kawakami, Kosei; Koenuma, Naoko; Shirahata, Toshikatsu; Momohara, Shigeki

doi:10.3109/14397595.2015.1109578

Cited by 13 publications

(9 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We observed 1-and 2-year abatacept retention rates of 77% and 53%, respectively, slightly lower than in similar studies. For example, the 1-and 2year abatacept retention rates in a 104-week study were reported to be 83.7% and 73.9%, respectively [9]. The lower retention rate in our study may have been due to our inclusion of a higher percentage of biologic-failure patients (56% vs. 38%).…”

Section: Discussionmentioning

confidence: 52%

“…Abatacept showed similar efficacy and safety when administered subcutaneously or intravenously, as well as low immunogenicity, in MTX-resistant Japanese RA patients [7,8]. Moreover, abatacept was shown to suppress joint destruction for 104 weeks in 92 Japanese RA patients [9], and a postmarketing surveillance (PMS) study showed that abatacept was safe and effective in Japanese RA patients [10]. In addition, some Japanese patients with established RA who attained clinical remission following abatacept treatment subsequently achieved biologic-free remission [11].…”

Section: Introductionmentioning

confidence: 91%

“…RA disease activity was assessed by measuring 28joint disease activity score with CRP (DAS28-CRP) at 0, 3,6,9,12,15,18,21 and 24 months. DAS28-CRP scores of < 2.3, !…”

Section: Efficacy Assessmentsmentioning

confidence: 99%

See 2 more Smart Citations

Multicenter, observational clinical study of abatacept in Japanese patients with rheumatoid arthritis

Ogawa

Ohashi

Ota

et al. 2019

Immunological Medicine

View full text Add to dashboard Cite

The aim of this study was to assess abatacept in rheumatoid arthritis (RA) patient. Patients (20 men, 89 women, aged 61.9 ± 10.4 y) who responded inadequately to conventional synthetic disease-modifying anti-rheumatic drug were treated with abatacept for 24-months. Disease activity score in 28 joints (DAS28-CRP) was evaluated. Of 109 patients, 82 (75.2%) were on methotrexate (MTX; mean dosage 9.0 ± 2.7 mg/week); 48 (44.0%) were naive to biologics and 61 (56.0%) had failed biologics. The 1-and 2-year retention rates were 77% and 53%, respectively. At 24months, the DAS28-CRP remission rates were 62.8% in the biologic-naïve patients, and 33.3% in the biologic-failure patients (p < .01), while the structural remission rates were 83.9% and 73.1%, respectively (p ¼ .461). Abatacept was equally effective in RA patients who were and were not on concomitant MTX. Biologic-naïve was associated with better clinical outcome. Abatacept was effective in patients who showed decreasing anti-CCP antibody titers or serum MMP-3 levels during treatment. Infection was the most frequent adverse effect of abatacept therapy. In conclusion, abatacept is more effective in biologic-naïve than in biologic-failure RA patients with or without concomitant use of MTX. Abatacept is more effective in RA patients with than without decreasing serum MMP-3 or anti-CCP antibody titers during treatment. ARTICLE HISTORY

show abstract

Section: Discussionmentioning

confidence: 52%

Section: Introductionmentioning

confidence: 91%

See 1 more Smart Citation

Multicenter, observational clinical study of abatacept in Japanese patients with rheumatoid arthritis

Ogawa

Ohashi

Ota

et al. 2019

Immunological Medicine

View full text Add to dashboard Cite

show abstract

“…We had reported that in patients with RA, abatacept treatment achieved structural remission in small joints independent of MTX treatment. [ 29 ] Therefore, our results demonstrate that abatacept with or without MTX may suppress radiographic progressive damage of large and small joints.…”

Section: Discussionmentioning

confidence: 65%

Change of ARASHI Scores for Large Joints in Rheumatoid Arthritis Patients Treated With Abatacept for Three Years: A Clinical Observational Study

Mochizuki¹,

Yano

Ikari

et al. 2020

Arch Rheumatol

Self Cite

View full text Add to dashboard Cite

Objectives This study aims to investigate large joint damage progression using the assessment of rheumatoid arthritis by scoring of large joint destruction and healing in radiographic imaging (ARASHI) score in patients with rheumatoid arthritis (RA) treated with abatacept for three years. Patients and methods A total of 71 consecutive patients with RA (7 males, 64 females; median age 68 years; range, 41 to 81 years) and joint lesions (141 shoulders, 139 elbows, 141 hips, 134 knees, and 142 ankles) treated with abatacept for three years were examined. Radiographic changes were assessed using the ARASHI score, and factors associated with radiographic progressive damage of large joints were analyzed using multivariate logistic regression. Results The three-year radiographic progressive damage rates for the upper and lower limb large joints were 18.3% and 22.5%, respectively. Rates for the shoulder and knee decreased significantly (p=0.025 and 0.039, respectively), whereas rate for the ankle increased significantly (p=0.043). Multivariate logistic regression analysis identified the baseline ARASHI status score as an independent predictor of progressive damage of upper limb large joints within three years (p=0.004; odds ratio, 1.17). The cutoff value of the ARASHI status score for the upper limb large joints was 4, as determined from the receiver operating characteristics curve. No significant predictors of progressive damage were identified in the lower limb large joints within three years. Conclusion The greatest suppression of the radiographic progressive damage of large joints was achieved for the shoulders and knees. Meanwhile, ankle damage progressed. Therefore, ankle joint damage should be monitored even in patients treated with abatacept. In the upper limbs, prescribing abatacept to patients with RA depending on their state of upper limb large joint damage may suppress damage progression.

show abstract

“…Abatacept, a recombinant protein that combines the extracellular region of CTLA-4 and human IgG, has been applied as a biopharmaceutical for treating arthritis and juvenile idiopathic arthritis. Abatacept has been reported to reduce joint pain in arthritis patients for 104 weeks [18]. The affinity of CTLA-4 to its ligands, CD80 and CD86, is more than ten times higher than that of CD28, T cell co-stimulatory protein, and another receptor for CD80 and CD86 [19, 20].…”

Section: Discussionmentioning

confidence: 99%

Immune inhibitory function of bovine CTLA-4 and the effects of its blockade in IFN-γ production

et al. 2019

View full text Add to dashboard Cite

BackgroundCytotoxic T-lymphocyte antigen 4 (CTLA-4) is known as an immune inhibitory receptor that is expressed on activated effector T cells and regulatory T cells. When CTLA-4 binds to CD80 or CD86, immunoinhibitory signals are transmitted to retain a homeostasis of the immune response. Recent studies have reported that CTLA-4 is upregulated in chronic infections and malignant neoplasms, contributing to host immune dysfunction. On the other hand, the blockade of CTLA-4 and CD80 or CD86 binding by antibody restores the immune response against these diseases. In a previous report, we indicated that the expression of CTLA-4 was closely associated with disease progression in cattle infected with the bovine leukemia virus (BLV). In this study, we established an anti-bovine CTLA-4 antibody to confirm its immune enhancing effect.ResultsBovine CTLA-4-Ig binds to bovine CD80 and CD86 expressing cells. Additionally, CD80 and CD86 bind to CTLA-4 expressing cells in an expression-dependent manner. Bovine CTLA-4-Ig significantly inhibited interferon-gamma (IFN-γ) production from bovine peripheral blood mononuclear cells (PBMCs) activated by Staphylococcus enterotoxin B (SEB). An established specific monoclonal antibody (mAb) for bovine CTLA-4 specifically recognized only with bovine CTLA-4, not CD28, and the antibody blocked the binding of CTLA-4-Ig to both CD80 and CD86 in a dose-dependent manner. The bovine CTLA-4 mAb significantly restored the inhibited IFN-γ production from the CTLA-4-Ig treated PBMCs. In addition, the CTLA-4 mAb significantly enhanced IFN-γ production from CTLA-4 expressing PBMCs activated by SEB. Finally, we examined whether a CTLA-4 blockade by CTLA-4 mAb could restore the immune reaction during chronic infection; the blockade assay was performed using PBMCs from BLV-infected cattle. The CTLA-4 blockade enhanced IFN-γ production from the PBMCs in response to BLV-antigens.ConclusionsCollectively, these results suggest that anti-bovine CTLA-4 antibody can reactivate lymphocyte functions and could be applied for a new therapy against refractory chronic diseases. Further investigation is required for future clinical applications.

show abstract

The efficacy of abatacept in Japanese patients with rheumatoid arthritis: 104 weeks radiographic and clinical results in clinical practice

Abstract: This study suggested efficacy of abatacept treatment in Japanese patient with RA for 104 weeks in daily clinical practice. Abatacept lead to suppress joint destruction for 104 weeks.

Cited by 13 publications

References 29 publications

Multicenter, observational clinical study of abatacept in Japanese patients with rheumatoid arthritis

Multicenter, observational clinical study of abatacept in Japanese patients with rheumatoid arthritis

Change of ARASHI Scores for Large Joints in Rheumatoid Arthritis Patients Treated With Abatacept for Three Years: A Clinical Observational Study

Immune inhibitory function of bovine CTLA-4 and the effects of its blockade in IFN-γ production

Contact Info

Product

Resources

About